DeepMed Research

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab

First Posted Date: 2007-11-09

Last Posted Date: 2010-12-30

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00556088

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

LBH589 and Gemcitabine in the Treatment of Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: LBH589, Gemcitabine

First Posted Date: 2007-10-29

Last Posted Date: 2013-08-19

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 17

Registration Number: NCT00550199

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: LBH589

First Posted Date: 2007-10-29

Last Posted Date: 2021-11-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 20

Registration Number: NCT00550277

Locations: 🇺🇸
Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 7 locations

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Vinflunine

First Posted Date: 2007-10-17

Last Posted Date: 2021-12-16

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 41

Registration Number: NCT00545766

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States

and more 9 locations

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Sorafenib

First Posted Date: 2007-10-16

Last Posted Date: 2013-04-01

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 45

Registration Number: NCT00544167

Locations: 🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Integrated Community Oncology Network, Jacksonville, Florida, United States
🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States

and more 5 locations

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Radiation: Radiation Therapy
Drug: Temozolomide
Drug: Sorafenib

First Posted Date: 2007-10-16

Last Posted Date: 2016-09-01

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 47

Registration Number: NCT00544817

Locations: 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 7 locations

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Pomalidomide
Drug: Gemcitabine

First Posted Date: 2007-10-08

Last Posted Date: 2013-03-13

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 23

Registration Number: NCT00540579

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Sorafenib

First Posted Date: 2007-09-28

Last Posted Date: 2013-02-27

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 13

Registration Number: NCT00536575

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: lenalidomide
Drug: Rituximab
Drug: Fludarabine

First Posted Date: 2007-09-27

Last Posted Date: 2017-01-16

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 64

Registration Number: NCT00536341

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
National Capital Clinical Research Consortium, Bethesda, Maryland, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 3 locations

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2007-04-04

Last Posted Date: 2022-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 110

Registration Number: NCT00456261

Locations: 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy